Skip to content

Will Exelixis’s Orphan Drug Cabozantinib For Medullary Thyroid Cancer Receive FDA Approval ? – SeekingAlpha.com Perspective

November 26, 2012

       SeekingAlpha.com’s November 26, 2012, article titled, “Exelixis’s Cabozantinib Should Receive FDA Approval, But Faces Long-Term Challenges”, is an interesting perspective on identifying whether or not Exelixis’s orphan Drug Cabozantinib will receive FDA Approval on Thursday, November 29, 2012, for Medullary Thyroid Cancer (MTC). 

        If Cabozantinib is approved by the FDA, it will be Exelixis’s 1st FDA-approved drug. The article goes on to discuss the medicine and science behind Cabozantinib, and the reasons for why the FDA would approve it. It is important to note that Exelixis will be seeking approval of Cabozantinib for other indications in the future.           

References

 Orphan Druganaut November 25, 2012 Blog Post titled, “Why Is November 29, 2012 Important For Exelixis’s Orphan Drug Cabozantinib For Medullary Thyroid Cancer ?”

Copyright © 2012-2013, Orphan Druganaut Blog.  All rights reserved.

Advertisements
One Comment
  1. Thanks for visiting the Orphan Druganaut Blog & providing the update – greatly appreciated !!

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: